Clinical trials
Pancreatic Tumor clinical trials
Below are recruiting pancreatic tumor clinical trials, each written for real people, not researchers. We’re tracking 227 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06505395RecruitingPhase 2
Octreotide injection for advanced neuroendocrine tumors
This trial is testing an injectable medicine called octreotide for people with advanced neuroendocrine tumors of the digestive system or pancreas. It aims to see if the medicine can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05245500RecruitingPhase 1
Study drug for solid tumors with MTAP gene deletion
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Phoenix, ArizonaAges 18 years+ - NCT04222413RecruitingPhase 1
Metarrestin for advanced solid tumors that spread
This Phase 1 trial studies metarrestin to see how safe it is and how well it works in people with advanced solid cancers that have spread or come back. You may be eligible if standard treatment options are no longer working or aren’t available.
Fairway, KansasAges 12–120 - NCT05477576RecruitingPhase 3
Lu-177–treated NET patients: new drug versus standard care
This Phase 3 trial tests RYZ101 versus standard of care in people with inoperable, well-differentiated SSTR-positive GI or pancreas neuroendocrine tumors (NETs) that keep growing after Lu-177 SSA. It may help by improving tumor control after your prior targeted radiation treatment.
Phoenix, ArizonaAges 18 years+ - NCT04924075RecruitingPhase 2
Belzutifan for cancers linked to VHL or HIF-2α changes
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Los Angeles, CaliforniaAges 12 years+ - NCT05737953Recruiting
Testing a lab test to identify pancreatic cyst tumor type
This study builds a “molecular marker” lab model using pancreatic cyst fluid taken during planned pancreatic surgery. It aims to help tell which pancreatic cystic tumors are which, based on fluid analysis.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04011982Recruiting
Study of tissue analysis after pancreatic cancer surgery
This trial studies and analyzes tissue samples from people who had surgery for exocrine pancreatic (pancreatic duct-type) cancer. It may help researchers better understand the disease biology and improve future care.
LyonAges 18 years+ - NCT06574373Recruiting
Finding new markers for pancreatic IPMN progression
This study looks for new markers in the blood or tissues of people with a pancreatic condition called IPMN. The goal is to find better ways to predict if IPMN might turn into cancer and to help choose the best treatment.
RomaAges 18 years+ - NCT05961982Recruiting
EUS-guided heat treatment for pancreatic cysts
This study tests whether an endoscopy-based “radiofrequency ablation” (controlled heating) can manage certain pancreatic cysts that look high-risk. It’s designed for people who are not good candidates for surgery, aiming to shrink or control the cyst safely.
Columbus, OhioAges 18 years+ - NCT06245330RecruitingPhase 1/Phase 2
Study of AST-001 for advanced solid tumors
This trial is testing a new drug called AST-001 for people with advanced solid tumors (including pancreatic cancer) that have not responded to standard treatments. The study aims to find the right dose and see how well the drug works.
Changchun, JinlinAges 18–70 - NCT04520932Recruiting
Radiofrequency treatment for small nonfunctioning pancreatic tumors
This trial tests whether heating (radiofrequency) treatment guided by a special ultrasound scope can control small pancreatic neuroendocrine tumors. It may help patients whose tumors are very small and do not release hormones.
MarseilleAges 18–80 - NCT06577532RecruitingEarly Phase 1
KRAS mRNA vaccine for advanced solid tumors
This early-phase trial is testing a new mRNA vaccine (ABO2102) designed to target KRAS mutations in advanced solid tumors. It may be an option if your cancer has a KRAS mutation and standard treatments are no longer working.
ShanghaiAges 18 years+ - NCT06340620Recruiting
Comparing a new ultrasound tool to the standard scope
This study compares a new, possibly easier-to-use ultrasound tool (EndoSound Vision System) to the standard echoendoscope for looking at organs like the pancreas, bile duct, or lymph nodes. If you are already scheduled for an endoscopic ultrasound, you may be able to join.
Orlando, FloridaAges 18–100 - NCT03334708Recruiting
Blood tests to study pancreas cancer and related conditions
This study checks whether blood-based tests can help learn about pancreas cancer and other pancreas conditions. It may help connect blood results with tumor biology to guide future care.
Middletown, New JerseyAges 18 years+ - NCT05380414Recruiting
Study of advanced pancreatic cancer using tumor tissue profiles
This study looks at advanced or metastatic pancreatic cancer patients and uses stored tumor tissue to learn what may predict treatment outcomes. You may be able to join if you have had limited prior chemotherapy and can provide an archived tissue sample.
LyonAges 18 years+ - NCT06008288RecruitingPhase 2
JAB-21822 for advanced pancreatic or other solid tumors with KRAS G12C
This study tests an experimental pill called JAB-21822 that targets a specific gene change (KRAS G12C) in advanced pancreatic cancer or other solid tumors. It's for people who have already tried standard chemotherapy and whose cancer has gotten worse or who couldn't handle the side effects.
Hefei, AnhuiAges 18 years+ - NCT07554560Recruiting
Nutrition Support for Pancreatic Cancer Patients
This study tests a nutrition intervention for people with pancreatic cancer who are having trouble eating or absorbing nutrients. The goal is to help patients maintain strength and improve their quality of life during cancer treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07595237RecruitingEarly Phase 1
Radioactive treatment for advanced solid tumors with Claudin18.2
This early-stage trial tests a new radioactive drug (177Lu-DOTA-SNA040) designed to target a protein called Claudin18.2 found on certain cancer cells. The drug delivers radiation directly to tumors in patients with advanced gastric, pancreatic, or bile duct cancers that have stopped responding to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06937112Recruiting
A new scan for early detection of certain cancers
This trial tests a new imaging agent (18F-FAPI) to see if it can help find tumors early in people with lung, thyroid, pancreatic, melanoma, or neuroendocrine cancers.
Nanjing, JiangsuAges 18–75 - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT05243082Recruiting
Ultrasound-guided heating treatment for pancreatic neuroendocrine tumors
This trial tests a procedure that uses an endoscope and ultrasound to heat (radiofrequency ablate) pancreatic neuroendocrine tumors. It may help shrink tumors while aiming to be a less invasive option.
OsloAges 18 years+ - NCT06121622Recruiting
Personalized 3D models for pancreatic neuroendocrine tumors
This study is testing a new way to make 3D models in the lab that look like your specific tumor. The goal is to better understand pancreatic neuroendocrine tumors and find personalized treatments.
Milan, MIAges 18 years+ - NCT05098197RecruitingEarly Phase 1
Study of TIL cell therapy for advanced liver, bile, or pancreas cancer
This trial studies a treatment called TIL therapy, which uses your own immune cells grown from a tumor sample, to treat advanced cancers of the liver/bile ducts or pancreas. It’s mainly for people whose standard treatments have already failed (or none exist), and who can safely provide tumor tissue for the cell preparation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05346536Recruiting
Test blood test for a specific type of pancreatic cancer cell
This trial looks for pancreatic cancer markers in a blood sample (“liquid biopsy”), focusing on cells that show a certain protein (AXL). It may help doctors detect and better track advanced pancreatic cancer before or during first-line treatment.
MontpellierAges 18 years+
Hear when a new Pancreatic Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic tumor?
- Yes. Clin2 currently lists 227 recruiting pancreatic tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.